|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, February 09, 2016 ) The Hepatitis B Virus (HBV) can cause both acute and chronic liver disease. HBV is typically transmitted through contact with infectious blood or bodily fluid, including vertical transmission from mother to child at birth and transmission via sexual intercourse. Risk factors of chronic hepatitis B (CHB) include unprotected sex with an infected partner, men who have sex with men (MSM), intravenous drug injection (IDU), and a previous history of a sexually transmitted disease (STD). CHB has a well-established comorbidity association with hepatitis C virus (HCV) infection, hepatitis D virus (HDV) infection, human immunodeficiency virus (HIV) infection, and alcohol abuse. The disease often starts as asymptomatic in the acute infection phase, with symptoms beginning to present 30 to 180 days from infection. When symptoms develop, they present as nausea, vomiting, loss of appetite, flu-like symptoms, and jaundice. Severe cases of HBV infection increase the risk of developing liver cancer and cirrhosis.
GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of chronic hepatitis B (CHB) in the 8MM, from 10,557,407 cases in 2014 to 10,861,653 cases in 2024, at an Annual Growth Rate (AGR) of 0.29% in the forecast period. The distribution of diagnosed prevalent chronic hepatitis B cases in the 8MM was greater in men (7,379,948 cases, 69.90% in 2014) than in women (3,177,459 cases, 30.10% in 2014). This skew towards men was found to be consistent across all markets.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=556458
GlobalDatas epidemiological forecast for the diagnosed prevalent cases of CHB are supported by age- and sex-specific data obtained from country-specific studies published in peer-reviewed journals, in which the study populations are representative of the general population in the respective markets. The diagnosed prevalent cases are further segmented into ALT level, HBV DNA level, HBeAg status, cirrhosis status, and co-infection with hepatitis C and HIV, thus providing a comprehensive view of the characteristics of CHB patients in the 8MM. Additionally, GlobalData epidemiologists used the same methodology across the 8MM, which allows for a meaningful comparison of the forecast diagnosed incident cases and diagnosed prevalent cases of CHB in these markets.
Scope
- The Chronic Hepatitis B (CHB) EpiCast Report provides an overview of the risk factors and global trends of CHB in the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and China). It includes a 10-year epidemiological forecast for total and diagnosed prevalent cases of CHB segmented by sex and in these markets. The diagnosed prevalent cases of CHB are further segmented by hepatitis B virus (HBV) DNA level (20,000IU/mL in the US and the 5EU, and 10,000IU/mL in Japan and China), alanine aminotransferase (ALT) level (=2 upper limit of normal [ULN] 2-5ULN and >5ULN), hepatitis e surface antigen (HBeAg) status, and the liver cirrhosis status.
- The CHB epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
Reasons to buy
The CHB EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global CHB market.
- Quantify patient populations in the global CHB market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CHB therapeutics in each of the markets covered.
- Identify the percentage of CHB diagnosed prevalent cases by various clinical segmentations.
Browse Detail Report With TOC @ http://www.researchmoz.us/epicast-report-chronic-hepatitis-b-epidemiology-forecast-to-2024-report.html
Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 9
3 Epidemiology 10
3.1 Disease Background 10
3.2 Risk Factors and Comorbidities 11
3.3 Global Trends 12
3.4 Forecast Methodology 14
3.4.1 Sources Used 15
3.4.2 Sources Not Used 24
3.4.3 Forecast Assumptions and Methods 25
3.5 Epidemiological Forecast of Chronic Hepatitis B (2014-2024) 31
3.5.1 Diagnosed Prevalent Cases of Chronic Hepatitis B 31
3.5.2 Age-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B 33
3.5.3 Sex-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B 36
3.5.4 Age-Standardized Diagnosed Prevalence of Chronic Hepatitis B 38
3.5.5 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBV DNA Level 39
3.5.6 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by ALT Level 41
3.5.7 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBeAg Status 42
3.5.8 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by Cirrhosis Status 43
3.5.9 Diagnosed Prevalent Cases of Chronic Hepatitis B with Co-infection of HIV and Hepatitis C 45
3.6 Discussion 46
3.6.1 Epidemiological Forecast Insight 46
3.6.2 Limitations of the Analysis 46
3.6.3 Strengths of the Analysis 47
4 Appendix 48
4.1 Bibliography 48
4.2 About the Authors 51
4.2.1 Epidemiologists 51
4.2.2 Reviewers 51
4.2.3 Global Director of Therapy Analysis and Epidemiology 52
4.2.4 Global Head of Healthcare 52
4.3 About GlobalData 53
4.4 About EpiCast 53
4.5 Disclaimer 54
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=556458
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Browse Our Latest Press Releases @ http://www.researchmoz.us/pressrelease
Researchmoz Global Pvt.Ltd
Researchmoz
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
